Literature DB >> 21670328

Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds.

Carol L Shields1, Carlos G Bianciotto, Pascal Jabbour, Aparna Ramasubramanian, Sara E Lally, Gregory C Griffin, Robert Rosenwasser, Jerry A Shields.   

Abstract

OBJECTIVE: To describe tumor control following intra-arterial chemotherapy (IAC) for retinoblastoma.
METHODS: A retrospective interventional series in which 17 patients were treated with ophthalmic artery injection of melphalan, 5 mg, was undertaken to determine retinoblastoma control.
RESULTS: Of 190 children with retinoblastoma, 17 (9%) were treated with IAC. Catheterization was successful in 37 of 38 attempts. The treatment was primary in 13 cases (1 failed catheterization) and secondary in 4. The median retinoblastoma base was 20 mm and the median retinoblastoma thickness was 9.0 mm. Iris neovascularization was present in 5 cases. Following IAC, complete response of the main tumor was found in 14 cases (88%) and partial response was found in 2 (12%). Eyes with complete response and followed up for a minimum of 1 year (n = 10) showed no solid tumor recurrence. Of 11 eyes with subretinal seeds, 9 (82%) had complete response, 1 (9%) had partial response, and 1 (9%) had recurrence. Of 9 eyes with vitreous seeds, 6 (67%) had complete response, 2 (22%) had partial response, and 1 (11%) had recurrence. Globe salvage was achieved in 8 of 12 eyes (67%) treated with primary IAC, including 2 of 2 group C eyes, 4 of 4 group D eyes, and 2 of 6 group E eyes according to the International Classification of Retinoblastoma. Globe salvage was achieved in 2 of 4 eyes (50%) treated secondarily after failure of other methods.
CONCLUSIONS: Of 12 eyes managed with IAC as primary treatment, globe salvage was achieved in 67%. Eyes classified as group C or D showed 100% globe salvage, whereas group E had 33% salvage. Of 4 eyes managed with IAC as secondary treatment, globe salvage was achieved in 50%.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21670328     DOI: 10.1001/archophthalmol.2011.150

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  56 in total

1.  Pathological findings in enucleated eyes after intravitreal melphalan injection.

Authors:  Fariba Ghassemi; Fahimeh Asadi Amoli
Journal:  Int Ophthalmol       Date:  2013-09-17       Impact factor: 2.031

2.  Ocular tumors: Triumphs, challenges and controversies.

Authors:  Ralph C Eagle
Journal:  Saudi J Ophthalmol       Date:  2013-07

3.  Retinoblastoma. Fifty years of progress. The LXXI Edward Jackson Memorial Lecture.

Authors:  Hans E Grossniklaus
Journal:  Am J Ophthalmol       Date:  2014-07-24       Impact factor: 5.258

4.  Selective ophthalmic arterial injection of melphalan for intraocular retinoblastoma: a 4-year review.

Authors:  Sherine Jue Ong; An-Ning Chao; Ho-Fai Wong; Kuan-Lyin Liou; Ling-Yuh Kao
Journal:  Jpn J Ophthalmol       Date:  2014-12-03       Impact factor: 2.447

5.  The National Registry of Retinoblastoma in Japan (1983-2014).

Authors: 
Journal:  Jpn J Ophthalmol       Date:  2018-05-30       Impact factor: 2.447

6.  Validating a nonhuman primate model of super-selective intraophthalmic artery chemotherapy: comparing ophthalmic artery diameters.

Authors:  Lauren C Ditta; Asim F Choudhri; Brian C Tse; Mark M Landers; Barrett G Haik; Jena J Steinle; J Scott Williams; Matthew W Wilson
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-27       Impact factor: 4.799

7.  Distinct Gene Expression Profiles Define Anaplastic Grade in Retinoblastoma.

Authors:  Lauren E Hudson; Pia Mendoza; William H Hudson; Alison Ziesel; G Baker Hubbard; Jill Wells; Bhakti Dwivedi; Jeanne Kowalski; Sandra Seby; Viren Patel; Eldon Geisert; Charles Specht; Hans E Grossniklaus
Journal:  Am J Pathol       Date:  2018-07-21       Impact factor: 4.307

8.  Combined intra-arterial chemotherapy and intravitreal melphalan for the treatment of advanced unilateral retinoblastoma.

Authors:  Ting-Yi Liang; Xiu-Yu Zhu; Xu-Ming Hua; Xun-Da Ji; Pei-Quan Zhao
Journal:  Int J Ophthalmol       Date:  2020-02-18       Impact factor: 1.779

9.  Superselective intraophthalmic artery chemotherapy in a nonhuman primate model: histopathologic findings.

Authors:  Brian C Tse; Jena J Steinle; Dianna Johnson; Barrett G Haik; Matthew W Wilson
Journal:  JAMA Ophthalmol       Date:  2013-07       Impact factor: 7.389

10.  Tumor Environment of Retinoblastoma, Intraocular Cancer.

Authors:  Dong Hyun Jo; Jin Hyoung Kim; Jeong Hun Kim
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.